The neonatal Fc receptor: Key to homeostasic control of IgG and IgG‐related biopharmaceuticals

IgG and albumin are the most abundant proteins in the circulation and have the longest half‐lives. These properties are due to a unique receptor, the neonatal Fc receptor (FcRn). Although FcRn is named for its function of transferring IgG across the placenta from maternal to fetal circulation, FcRn functions throughout life to maintain IgG and albumin concentrations. FcRn protects IgG and albumin from intracellular degradation and recycles them back into the circulation. Clinical trials have confirmed that pathogenic antibodies can be depleted by blocking this homeostatic function of FcRn. Moreover, understanding the molecular interactions between IgG and FcRn has resulted in the design of therapeutic monoclonal antibodies with more efficacious pharmacokinetics. As a result of genetic engineering these monoclonals can be delivered at lower doses and at longer intervals. More recent findings have demonstrated that FcRn enhances phagocytosis by neutrophils, immune complex clearance by podocytes and antigen presentation by dendritic cells, macrophages, and B cells. This minireview highlights the relevance of FcRn to transplantation.

[1]  A. Manning,et al.  M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study , 2018, Clinical pharmacology and therapeutics.

[2]  R. Wells,et al.  Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. , 2018, Blood advances.

[3]  R. Ober,et al.  Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans , 2018, The Journal of clinical investigation.

[4]  Zhao-Xue Yu,et al.  Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.

[5]  Denise M O'Hara,et al.  Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics , 2017, mAbs.

[6]  R. Lledo-Garcia,et al.  The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study , 2017, Science Translational Medicine.

[7]  Stephen R. Comeau,et al.  Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody , 2017, The Journal of Biological Chemistry.

[8]  R. Ober,et al.  Engineered clearing agents for the selective depletion of antigen-specific antibodies , 2017, Nature Communications.

[9]  A. Yamniuk,et al.  Fc‐Silent Anti‐CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  T. Igawa,et al.  Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody , 2017, mAbs.

[11]  P. Späth,et al.  Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations , 2017, Archivum Immunologiae et Therapiae Experimentalis.

[12]  S. Vermeire,et al.  A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease , 2016, The American Journal of Gastroenterology.

[13]  K. Howard,et al.  Albumin-based drug delivery: harnessing nature to cure disease , 2016, Molecular and Cellular Therapies.

[14]  N. Baroukh,et al.  IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding , 2016, The Journal of Immunology.

[15]  P. Ramsland,et al.  Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. , 2015, Molecular immunology.

[16]  K. Schwarz,et al.  β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. , 2015, The Journal of allergy and clinical immunology.

[17]  W. Lencer,et al.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin , 2015, The Journal of Immunology.

[18]  J. Biedenkapp,et al.  Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates , 2015, Front. Immunol..

[19]  Inger Sandlie,et al.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..

[20]  Thomas Emrich,et al.  Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.

[21]  M. Baranyi,et al.  Transgenic Rabbits That Overexpress the Neonatal Fc Receptor (FcRn) Generate Higher Quantities and Improved Qualities of Anti-Thymocyte Globulin (ATG) , 2013, PloS one.

[22]  N. Baroukh,et al.  Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies , 2013, mAbs.

[23]  A. Kaplan Therapeutic plasma exchange: A technical and operational review , 2013, Journal of clinical apheresis.

[24]  B. Carr,et al.  Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.

[25]  E. Fiebiger,et al.  Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8−CD11b+ dendritic cells , 2011, Proceedings of the National Academy of Sciences.

[26]  D. Roopenian,et al.  The Neonatal FcR-Mediated Presentation of Immune-Complexed Antigen Is Associated with Endosomal and Phagosomal pH and Antigen Stability in Macrophages and Dendritic Cells , 2011, The Journal of Immunology.

[27]  R. Kuijpers,et al.  The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha , 2011, British Journal of Ophthalmology.

[28]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[29]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[30]  R. Ober,et al.  Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice , 2009, Proceedings of the National Academy of Sciences.

[31]  J. Andersen,et al.  Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.

[32]  C. T. Hehir,et al.  Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn , 2008, Proceedings of the National Academy of Sciences.

[33]  A. Shaw,et al.  Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism1 , 2007, The Journal of Immunology.

[34]  A. Bitonti,et al.  Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade , 2007, The Journal of Immunology.

[35]  G. Vidarsson,et al.  FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. , 2006, Blood.

[36]  G. Bein,et al.  A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoter , 2006 .

[37]  D. Roopenian,et al.  Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.

[38]  R. Ober,et al.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.

[39]  P. Hudson,et al.  Engineered antibodies , 2003, Nature Medicine.

[40]  C. Anderson,et al.  The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Jin‐Kyoo Kim,et al.  Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice , 1996, European journal of immunology.

[42]  M. Uhlén,et al.  Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. , 1996, The Journal of pharmacology and experimental therapeutics.

[43]  K. Mostov,et al.  An Fc receptor structurally related to MHC class I antigens , 1989, Nature.

[44]  J. Kraehenbuhl,et al.  Receptor-mediated transport of IgG , 1984, The Journal of cell biology.

[45]  F. W. Brambell The transmission of immunity from mother to young and the catabolism of immunoglobulins. , 1966, Lancet.

[46]  F. W. R. BRAMBELL,et al.  A Theoretical Model of γ-Globulin Catabolism , 1964, Nature.

[47]  R. Porter The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. , 1959, The Biochemical journal.